Psoriasis

Common Name(s)

Psoriasis

Psoriasis is a chronic (long-lasting) skin condition that causes cells to grow too quickly and results in red, scaly, and occasionally itchy patches on the skin. In normal skin, cells flake off from the surface and are replaced by new cells every four weeks. In people with psoriasis, new cells form and quickly move to the surface of the skin, forming thick patches (plaques) that typically appear on the elbows, knees, scalp, lower back, hands, or feet. These patches are usually dry and itchy. If scraped or picked, they can also bleed. In some cases of psoriasis, the areas where bones meet (joints) may also become swollen and stiff, which is called psoriatic arthritis. Psoriasis can be mild, causing small areas of rash, or severe, causing large areas of raised, red and loose plaques. Symptoms of psoriasis tend to come and go. Risk factors that can lead to the return of symptoms (flare-ups) include a dry climate, infections, stress, dry skin and certain medications.

The exact cause of psoriasis is unknown. However, it is thought to be an autoimmune disease, which means something causes the body’s immune system to attack itself, mistaking healthy cells for something foreign (from outside the body). It is believed that both genetic and environmental factors play a role in psoriasis. In order to diagnose psoriasis, your doctor will gather a medical history and perform a physical exam that focuses on the skin. Your doctor may also remove and examine a small piece of the affected skin (skin biopsy). There is no cure for psoriasis. However, there are many treatment options that may help control the symptoms. These include creams that can be applied to the surface of the skin (topical), oral medications, moisturizers, and light therapy. If you or your child have been diagnosed with psoriasis, talk with your doctor to decide which treatment option is best for you.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Psoriasis" for support, advocacy or research.

National Psoriasis Foundation

Our mission is to find a cure for psoriasis and psoriatic arthritis and to eliminate their devastating effects through research, advocacy and education.

Last Updated: 26 Jul 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Psoriasis" for support, advocacy or research.

National Psoriasis Foundation

Our mission is to find a cure for psoriasis and psoriatic arthritis and to eliminate their devastating effects through research, advocacy and education.

http://www.psoriasis.org/

Last Updated: 26 Jul 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

General Resources

For scientists and medical professionals

Information about how to apply for National Psoriasis Foundation research grants and fellowships, our medical journal and other science-related materials for medical professionals.

Updated 15 Nov 2012

Go To URL
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Psoriasis" returned 2020 free, full-text research articles on human participants. First 3 results:

Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis.
 

Author(s): Amy S Paller, Elaine C Siegfried, David M Pariser, Kara Creamer Rice, Mona Trivedi, Jan Iles, David H Collier, Greg Kricorian, Richard G Langley

Journal: J. Am. Acad. Dermatol.. 2016 Feb;74(2):280-7.e1-3.

 

There are no systemic therapies approved in the United States to treat pediatric psoriasis.

Last Updated: 18 Jan 2016

Go To URL
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
 

Author(s): Phoebe Rich, Melinda Gooderham, Hervé Bachelez, Joana Goncalves, Robert M Day, Rongdean Chen, Jeffrey Crowley

Journal: J. Am. Acad. Dermatol.. 2016 Jan;74(1):134-42.

 

In the phase III double-blind Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2, apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in moderate to severe psoriasis.

Last Updated: 25 Dec 2015

Go To URL
Expression of apoptosis regulating proteins p53 and bcl-2 in psoriasis.
 

Author(s): Nikhil Moorchung, Biju Vasudevan, S Dinesh Kumar, Archit Muralidhar

Journal: Indian J Pathol Microbiol. ;58(4):423-6.

 

Dysfunctional apoptosis has an important role in the development of several skin diseases. Psoriatic keratinocytes possess an enhanced ability to resist apoptosis, which might be one of the key pathogenetic mechanisms in psoriasis. P53 and bcl-2 are two proteins which control apoptosis. ...

Last Updated: 9 Nov 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Psoriasis" returned 268 free, full-text review articles on human participants. First 3 results:

An Exploration of the Role of MicroRNAs in Psoriasis: A Systematic Review of the Literature.
 

Author(s): Run-Yue Huang, Li Li, Mao-Jie Wang, Xiu-Min Chen, Qing-Chun Huang, Chuan-Jian Lu

Journal: Medicine (Baltimore). 2015 Nov;94(45):e2030.

 

Psoriasis is recently characterized by a specific microRNAs (miRNAs) expression profile, which guides the researchers' efforts to explore the therapeutic targets and objective biomarkers that reflect the diagnosis and disease activity in clinical use for psoriasis.The paper presents ...

Last Updated: 12 Nov 2015

Go To URL
Apremilast in the treatment of psoriasis and psoriatic arthritis.
 

Author(s): M Gooderham, K Papp

Journal: Skin Therapy Lett.. ;20(5):1-6.

 

Phosphodiesterase 4 (PDE4) is a key enzyme in the regulation of immune responses of inflammatory diseases through degradation of the second messenger, cyclic adenosine 3',5'-monophosphate (cAMP). Apremilast, a selective PDE4 inhibitor, has been shown to reduce the production of pro-inflammatory ...

Last Updated: 19 Sep 2015

Go To URL
Biomarkers of An Autoimmune Skin Disease--Psoriasis.
 

Author(s): Shan Jiang, Taylor E Hinchliffe, Tianfu Wu

Journal: Genomics Proteomics Bioinformatics. 2015 Aug;13(4):224-33.

 

Psoriasis is one of the most prevalent autoimmune skin diseases. However, its etiology and pathogenesis are still unclear. Over the last decade, omics-based technologies have been extensively utilized for biomarker discovery. As a result, some promising markers for psoriasis have ...

Last Updated: 20 Oct 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
 

Status: Recruiting

Condition Summary: Psoriasis; Plaque Type Psoriasis; Moderate to Severe Plaque Psoriasis

 

Last Updated: 17 May 2016

Go to URL
Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris
 

Status: Recruiting

Condition Summary: Psoriasis; Psoriasis Vulgaris

 

Last Updated: 1 Feb 2010

Go to URL
Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis
 

Status: Recruiting

Condition Summary: Plaque Psoriasis; Psoriasis

 

Last Updated: 7 Mar 2016

Go to URL